Nefiracetam for Health & Longevity

Evidence Review created on 09/12/2026 using AI4L / Opus 5

Also known as: DM-9384, DZL 221, Translon, N-(2,6-dimethylphenyl)-2-(2-oxopyrrolidin-1-yl)acetamide

Motivation

Nefiracetam is a laboratory-made compound built on the same chemical skeleton as piracetam, the first of the cognition-enhancing drugs. It was created in Japan in the late 1980s as an oral medication for the thinking and mood problems that follow a stroke. What makes it unusual is that it does not switch on one receptor; it raises the gain on several of the brain’s signaling systems at once. It has never been approved as a medicine anywhere, yet it still circulates as a research chemical and as an ingredient in memory products.

Its developer took it through full-scale human testing for stroke aftereffects and for dementia, then abandoned the program in 2002. Interest survived for two reasons: a motivation signal that later stroke research picked up, and a striking set of organ injuries seen in dogs at very high doses, only partly reproduced in other animals.

This review examines what the human and animal evidence establishes about nefiracetam’s effects on thinking, mood and motivation, what its safety record does and does not show, how the body handles it, and what use, monitoring and sourcing involve in practice.

Benefits - Risks - Protocol - Conclusion

Grokipedia

Nefiracetam

The most complete single reference on the compound: it separates human tolerability from the dog-only organ toxicity, explains the metabolite behind that toxicity, and documents regulatory status country by country.

Examine

Nefiracetam

Grades the human evidence base as one trial in 137 participants, gives a supplement-scale dosing range well below the trial doses, and argues the dog toxicity is species-specific.

ConsumerLab

No ConsumerLab article on nefiracetam exists; a direct site search returns no results. ConsumerLab tests retail dietary supplements and does not cover unapproved investigational drugs, which nefiracetam is in the United States and the European Union and which is prescription-only in Australia.

Systematic Reviews

This section lists the systematic reviews (structured searches that appraise all studies on a question) and meta-analyses (statistical pooling of several studies) that report on nefiracetam, chiefly in relation to post-stroke apathy (clinically, a loss of motivation and initiative) and depression.

Treatment of apathy in stroke patients: a systematic review - Ruiz-Franco et al., 2025

The only systematic review covering nefiracetam directly; it judges the compound’s results mixed, varying with dose and with whether depression is also present.
Comparative efficacy and acceptability of antidepressant treatment in poststroke depression: a multiple-treatments meta-analysis - Sun et al., 2017

Pools twelve trials of ten agents and ranks nefiracetam last for reducing depression scores after stroke, placing it below placebo on the efficacy scale.

Nefiracetam involves a trade-off between a possible motivational benefit and an unresolved organ-toxicity signal. Both papers above address the claimed effect. The principal risk side is unrepresented: no systematic review or meta-analysis of nefiracetam’s safety, reproductive toxicity or renal toxicity has been published, so the risk evidence below rests on primary toxicology reports. Nearly all of those reports, and the studies of how the body handles the drug that are cited from here on, were produced by Daiichi Pharmaceutical, the company that owned the compound and that also funded the randomized stroke trials — a direct financial interest in the outcome that colors most of the evidence base cited throughout this review.

Mechanism of Action

Nefiracetam is fat-soluble, enters the brain readily, and amplifies signals already in progress rather than switching a receptor on by itself. Its best-characterized action is at nicotinic acetylcholine receptors — the switches flipped by acetylcholine, the memory transmitter. At sub-micromolar concentrations it produces a long-lasting current increase through the α4β2 subtype via a Gs-protein pathway (a cell’s internal signal relay), and raises acetylcholine release and choline uptake. It separately strengthens the NMDA (N-methyl-D-aspartate) receptor, a glutamate-gated channel central to learning, by activating protein kinase C (an enzyme that switches other proteins on) and easing the magnesium block that keeps the channel shut. Both routes converge on CaMKII (calcium/calmodulin-dependent protein kinase II, a memory-consolidating enzyme); blocking it abolishes the enhancement of long-term potentiation, the lasting strengthening of connections between nerve cells.

Mechanistic accounts compete: one holds that nefiracetam binds the GABA-A (gamma-aminobutyric acid type A) receptor — the brain’s main calming switch — with an affinity recorded in a review of the racetam class, the other that it has no direct receptor affinity at all and works only as an indirect modulator through kinases. The distinction is unresolved.

It is non-selective across the cholinergic (acetylcholine-based), glutamatergic (glutamate-based), GABA-ergic and monoamine (dopamine, serotonin and noradrenaline) systems, with bell-shaped concentration-response curves. It distributes widely, has a half-life of 3–5 hours (metabolites 7.8–21.9 hours), and is cleared mainly by hepatic CYP3A4 (the liver enzyme that handles most medicines), with a minor contribution from CYP1A2 (which also clears caffeine); under 10% leaves unchanged in urine.

Historical Context & Evolution

Nefiracetam was discovered by Daiichi Seiyaku (now Daiichi Sankyo) in the late 1980s under the development code DM-9384. The intended use was never cognitive enhancement in healthy adults: it was designed as an oral medication for the thinking and behavior problems left by cerebrovascular disease (disease of the brain’s blood vessels) and for dementia. Preclinical work through the early 1990s showed it reversing chemically induced memory loss in rodents and protecting learning after experimental stroke, and the safety package — carcinogenicity, mutagenicity and dependence studies — came back clean apart from organ findings in dogs.

The drug reached late-stage testing in Japan for post-stroke sequelae and vascular dementia. In February 2002 the company withdrew its Japanese application after a revised late-stage trial did not show sufficient efficacy, and development stopped worldwide.

What the historical research actually found is more mixed than the shutdown implies. Early Japanese studies reported gains on dementia rating scales; the revised trial did not reproduce them, and a later review of the drug class records the cognitive failure in stroke patients while noting the motivational signal that emerged afterwards. Interest moved into health optimization from that residue: a compound with a benign human tolerability record, a plausible cholinergic mechanism, and one positive motivation finding that nobody has since had the funding to confirm or refute.

Expected Benefits

High 🟩 🟩 🟩

No benefit reaches High: no clinical endpoint or validated human rating scale has moved in nefiracetam’s favor in more than one trial.

Medium 🟩 🟩

No benefit reaches Medium: the two randomized trials that measured a validated human scale disagree with each other, which puts their findings in the conflicting-human-data class rather than the single-trial class.

Low 🟩

Reduced Apathy After Stroke ⚠️ Conflicted

Apathy is common after stroke and predicts poorer recovery. In the 70-patient apathy subgroup of a randomized trial, 900 mg daily outperformed 600 mg and placebo; a second, far smaller randomized trial found no difference. Net: a real but unreplicated signal, seen only alongside depression.

Magnitude: Apathy Scale scores fell significantly further on 900 mg/day than on 600 mg/day or placebo over 12 weeks (n = 70); in the replication attempt (n = 13) scores fell 7.0 points overall, 95% confidence interval (the range within which the true value most likely sits) −14.6 to 0.6, with no separation between arms.

Improved Mood in Severe Post-Stroke Depression ⚠️ Conflicted

The main 159-patient randomized trial missed its primary depression endpoint, but the most severely depressed fifth improved on 900 mg daily. A pooled comparison of ten agents later ranked nefiracetam last. Net: no general mood effect, with a possible narrow one at the severe end.

Magnitude: Response exceeded 70% and remission exceeded 40% on both nefiracetam and placebo, leaving no drug-versus-placebo gap; in the pooled comparison the standardized mean difference (a common yardstick that puts different rating scales on one scale) versus placebo was 0.51, the weakest of ten agents, with positive values favoring placebo.

Speculative 🟨

Memory and Learning Enhancement

Repeated dosing improved memory in animal models of memory loss, and nefiracetam enhances long-term potentiation in the hippocampus. A development profile and a class review record no human cognitive gain; the basis is animal only.

Neuroprotection After Reduced Brain Blood Flow

In rats with blocked brain vessels, delayed dosing durably restored maze learning and raised brain-derived neurotrophic factor, a nerve-growth protein. The basis is animal and cell work only; no human outcome study exists.

Suppression of Established Seizures

Oral dosing dose-dependently shortened electrical and motor seizures in rats with fully established seizure circuits, though unlike levetiracetam it did not slow their build-up. Evidence is animal-only; no human epilepsy trial was run.

Relief of Nerve-Injury Pain

In mice with nerve injury, nefiracetam reversed pain hypersensitivity through a non-opioid route while leaving normal animals unaffected. Purely preclinical: no human study of nerve-injury pain has been performed.

Reduced Anxiety

Potentiation of the brain’s main calming receptor and animal mood-model data underpin user reports of calm. No controlled human anxiety measurement exists; the basis is mechanistic and anecdotal.

Benefit-Modifying Factors

CYP3A4 and CYP1A2 activity: Clearance runs mainly through CYP3A4, so carriers of high-activity CYP3A5 alleles (CYP3A5 is a sister enzyme to CYP3A4) or fast-metabolizing CYP1A2 variants hold lower blood levels at a given dose and may see less effect.
APOE4 and COMT status: APOE4 (a gene variant raising Alzheimer’s risk) and COMT (the enzyme clearing dopamine from the frontal cortex) both shape response to cholinergic and dopamine-touching agents; neither has been tested with nefiracetam, so any modification is inferred, not shown.
Baseline symptom severity: The only dose-responsive human signal appeared in the most severely depressed fifth of a stroke cohort and in patients meeting formal apathy criteria. Adults starting from normal mood and motivation have no measured headroom to gain.
Baseline choline availability: The compound accelerates acetylcholine turnover and choline uptake. Low dietary choline plausibly caps the cholinergic effect and is the conventional explanation for headache; this link is mechanistic rather than trial-tested.
Pre-existing cerebrovascular or cholinergic disease: Every positive human finding comes from stroke survivors. Benefit in intact adults has never been demonstrated, and the animal work consistently shows larger effects where a deficit was induced first.
Sex: Both randomized trials were male-predominant and neither reported sex-stratified efficacy, so no sex difference in benefit can be stated in either direction — a genuine gap rather than a null finding.
Age: Trial populations were older stroke and dementia patients, in whom cholinergic tone is already falling. Against that, liver CYP3A4 activity declines with age, raising exposure at a fixed dose in the oldest users.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: no adverse outcome has been documented in more than one controlled human trial; the organ toxicities on record are animal findings.

Medium 🟥 🟥

Mild Gastrointestinal Upset

Nausea and abdominal discomfort are the adverse events most often attributed to nefiracetam. In the 12-week randomized post-stroke trial at 600–900 mg daily, treatment was tolerated without an excess of withdrawals over placebo. Severity was mild and reversible on stopping. A review of the drug class reports the same pattern across related compounds, none of which carries a serious gastrointestinal warning.

Magnitude: The direction is an increase in mild, self-limiting nausea and abdominal discomfort at 600–900 mg/day over 12 weeks, most likely when doses are taken without food; the published trial reports give no event-rate figure for individual gastrointestinal events.

Low 🟥

Headache, Nervousness, and Fatigue

Headache, jitteriness and fatigue are the complaints most often reported by people using nefiracetam bought as a research chemical; headache is conventionally blamed on accelerated acetylcholine turnover outrunning choline supply. No controlled trial counted these events. A review of the racetam class describes the same profile.

Magnitude: Not quantified in available studies. No controlled trial has counted headache, nervousness or fatigue separately for nefiracetam, so the only frequency information comes from uncollated user reports.

Adulterated or Mislabeled Product

Because no approved nefiracetam product exists, every unit comes from an unregulated supply chain. When researchers assayed retail cognitive-enhancement products labeled with other racetams, most declared amounts were wrong and undeclared drugs appeared. Nefiracetam itself was not assayed, so the finding is indirect.

Magnitude: In that analysis of ten racetam-labeled products, 9 of 12 declared drug quantities (75%) were inaccurate, individual products contained as many as four unapproved drugs, and a single recommended serving delivered up to four times a pharmaceutical dose.

Speculative 🟨

Testicular Injury and Reduced Sperm Quality

Dogs given 180–300 mg/kg daily for four weeks developed shrunken sperm-producing tubules, reduced sperm motility and malformed sperm, preceded by falling testicular testosterone; rats showed the same at 1500 mg/kg. No human data exist.

Renal Papillary Necrosis

Renal papillary necrosis (death of the innermost kidney tissue) appeared in beagles at 300 mg/kg daily for 11 weeks, driven by the dog-specific metabolite M-18. Humans do not form M-18; rats and monkeys were unaffected.

Hemorrhagic Bladder Lesions

High-dose dogs also developed bleeding bladder lesions; cell work traced this to the same M-18 metabolite damaging bladder lining cells. Again dog-specific, at doses far above any human intake.

Sedation, Unsteadiness, and Additive Sedative Effects

General pharmacology screens in mice found reduced movement, unsteady gait and prolonged barbiturate anesthesia at high doses. Nothing comparable is documented in people, but the calming-receptor action makes additive sedation plausible.

Risk-Modifying Factors

CYP3A4 and CYP3A5 genotype: Poor CYP3A4 metabolizers, and non-expressers of CYP3A5, clear the parent compound more slowly and hold higher peak levels, which shifts every dose-dependent effect upward at an unchanged milligram intake.
Baseline kidney biomarkers: Reduced filtration concentrates metabolites that leave by the renal route. A creatinine above 2.0 mg/dL or estimated filtration below 25 mL/min was a formal exclusion in the sponsor-run Alzheimer’s trial.
Baseline reproductive biomarkers: Low-normal morning total testosterone or already-impaired sperm parameters leave no reserve if the animal testicular signal proves to apply to humans at some unknown exposure.
Sex: The entire documented organ-toxicity signal is male-reproductive. Against that, no reproductive or developmental human data exist for women, and pregnancy and lactation have never been studied at all.
Kidney, liver and seizure history: Chronic kidney disease, liver enzymes above three times the upper reference limit, and an active seizure disorder were all trial exclusions; concurrent anti-inflammatory drugs compound the kidney pathway implicated in the dog lesion.
Age: Liver CYP3A4 activity and kidney filtration both fall with age, so the same milligram dose produces higher exposure in the oldest users, who also carry the heaviest burden of interacting medicines.

Key Interactions & Contraindications

Strong CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin, ritonavir, grapefruit juice): Caution; they block the main clearance route and raise exposure, amplifying every dose-dependent effect. Mitigation: avoid the combination, or reduce the nefiracetam dose by roughly half.
CYP3A4 inducers (rifampin, carbamazepine, phenytoin, St. John’s wort): Monitor; they accelerate clearance and can drop blood levels far enough to make any effect disappear. Mitigation: separate the agents rather than escalating the nefiracetam dose blindly.
CYP1A2 inhibitors (fluvoxamine, ciprofloxacin) and inducers (tobacco smoke): Monitor; CYP1A2 is a minor clearance route, so the shift in exposure is modest but adds to any CYP3A4 effect already present. No dose change is usually needed.
Over-the-counter anticholinergics (diphenhydramine, doxylamine, dimenhydrinate): Caution; they block the acetylcholine signaling nefiracetam is taken to strengthen, cancelling the intended effect and worsening confusion in older users. Mitigation: substitute a non-sedating antihistamine.
Over-the-counter anti-inflammatory drugs (ibuprofen, naproxen, aspirin): Caution; they suppress kidney prostaglandins (local molecules that protect kidney tissue), the pathway implicated in the dog kidney lesion. Mitigation: limit continuous concurrent use and check kidney function.
Cholinergic supplements with additive effects (alpha-GPC — a choline source, citicoline, huperzine A, nicotine): Monitor; additive acetylcholine load can produce nausea, sweating and headache. Mitigation: choline donors are usually taken deliberately to offset headache, so escalate one agent at a time.
GABA-ergic supplements and depressants with additive effects (phenibut, valerian, kava, alcohol, benzodiazepines, zolpidem, opioids): Caution; nefiracetam potentiates the same calming receptor, and in animals it prolonged barbiturate anesthesia. Mitigation: avoid combining, particularly before driving.
Other racetams and cognitive agents (piracetam, aniracetam, donepezil, galantamine, memantine): Monitor; donepezil and galantamine add cholinergic load, while memantine blocks the glutamate channel nefiracetam strengthens and may cancel it. Mitigation: do not stack without a clear reason.

Populations who should avoid Nefiracetam:

Men attempting conception, or within three months of doing so — the sponsor’s own trial excluded them over possible effects on sperm production
Pregnancy and lactation — no human reproductive data of any kind
Chronic kidney disease with creatinine clearance below 25 mL/min, blood urea nitrogen above 30 mg/dL, or creatinine above 2.0 mg/dL
Liver impairment with alanine or aspartate aminotransferase (liver enzymes that spill into the blood when liver cells are damaged) above three times the upper reference limit, or total bilirubin above 2.0 mg/dL
Active seizure disorder, or any anticonvulsant medication, which trial protocols excluded outright
Known hypersensitivity to nefiracetam
Anyone under 18 — the compound has never been studied in that age group

Risk Mitigation Strategies

Low starting dose with slow titration: Protocols typically begin at 100–200 mg once daily for 1–2 weeks before splitting and increasing, which limits nausea, headache and sedation — the three effects most tied to dose.
Hard ceiling at 900 mg daily: No human has been studied above this, the highest dose in a 12-week randomized trial. Staying below it avoids exposure territory where only animal toxicity data exist.
Pair with a choline donor: Alpha-GPC 300 mg or citicoline 250 mg daily alongside each dose addresses the choline shortfall conventionally blamed for racetam headache, the most common reason users abandon the compound.
Take with dietary fat and food: The compound is fat-soluble and food delays but does not reduce absorption; dosing with a fat-containing meal blunts the nausea and abdominal discomfort seen at 600–900 mg.
Baseline and 12-week kidney panel with urinalysis: Creatinine, filtration rate, blood urea nitrogen plus urine volume, specific gravity and osmolality catch the earliest markers of the dog kidney lesion should it prove translatable.
Baseline and 12-week reproductive checks for men: Morning total testosterone, estradiol and, for anyone planning conception, semen analysis directly track the one organ system where animal toxicity was unambiguous.
Avoid sedative and alcohol combinations: Nefiracetam potentiates the brain’s calming receptor and prolonged barbiturate anesthesia in animals, so abstaining from concurrent depressants prevents additive sedation and unsteadiness.
Fixed 12-week review point: Stopping to reassess at 12 weeks matches the longest human exposure ever formally studied and prevents open-ended use in a safety vacuum.
Third-party certificate of analysis before first use: Identity and purity testing by mass spectrometry, plus heavy-metal and residual-solvent screens, mitigates the mislabelling and adulteration documented across racetam-labeled retail products.

Therapeutic Protocol

Trial-grade regimen: The only regimen with controlled human data is 600 mg or 900 mg daily in divided doses for 12 weeks; only the 900 mg arm produced any signal, on apathy and severe depression.
Self-directed regimen: David Tomen’s Nootropics Expert guidance gives 100–900 mg daily in divided doses; Examine’s supplement-scale range is narrower at 150–450 mg daily split across three administrations. Both sit below the trial doses.
Competing approaches: The conventional route for post-stroke apathy uses approved agents — escitalopram, donepezil, methylphenidate — with published trial support. The self-directed route uses nefiracetam without approval or oversight. Neither is the default here.
Best time of day: Doses are placed in the morning and early afternoon, keeping the 3–5 hour parent exposure inside waking hours and avoiding overlap with sleep onset given the calming-receptor action.
Half-life and accumulation: The parent compound clears with a 3–5 hour half-life; metabolites persist 7.8–21.9 hours and reach steady state by day 7, so effects are judged after a week, not after one dose.
Split rather than single dosing: Anything above 200 mg total is conventionally divided, matching both the human pharmacokinetic study design of 200 mg three times daily and the practitioner guidance of two daily administrations.
Take with fat: Absorption depends on lipid solubility, so administration accompanies a meal containing fat, or a tablespoon of olive or coconut oil, rather than on an empty stomach.
Genetic influences on dose: Fast CYP3A4 or CYP1A2 metabolizers clear the compound quickly and sit at the upper end of any range; slow metabolizers and CYP3A5 non-expressers start at the lower end. No pharmacogenetic dosing study exists.
Sex differences in dosing: No trial reported sex-stratified dosing or response, so no differentiated regimen can be justified; the only sex-specific consideration is the male reproductive monitoring described above.
Age adjustment: Because liver CYP3A4 activity and kidney filtration decline with age, adults past roughly 70 start at 100 mg daily and escalate more slowly than the standard schedule.
Baseline biomarkers guiding response: Formal apathy or depression scoring at baseline defines whether there is anything measurable to change; without a documented deficit no response can be distinguished from fluctuation.
Pre-existing conditions guiding dose: Reduced kidney filtration or raised liver enzymes both slow clearance, so protocols in that setting cap the total daily dose well below 600 mg or avoid the compound entirely.

Discontinuation & Cycling

Not a lifelong agent: The longest controlled human exposure is 12 weeks. Nothing supports indefinite use, and the standard pattern is a defined course followed by a deliberate stop and reassessment.
No documented withdrawal syndrome: A rat dependence study using drug-admixed food and intravenous self-administration found no physical dependence and no reinforcing behavior, and no human withdrawal reports exist.
Tapering rarely required: With a 3–5 hour parent half-life and no withdrawal signal, abrupt cessation carries no known pharmacological penalty; a one-week step-down is used mainly to make any loss of effect easier to attribute.
Cycling has no efficacy evidence: Nothing shows tolerance developing, so cycling is not needed to preserve response. Where it is used, the rationale is limiting cumulative exposure, not maintaining effect.
Stopping for monitoring reasons: Any rise in creatinine, fall in urine concentrating ability, or drop in morning testosterone is treated as a stop signal rather than a dose-reduction signal, given the animal organ findings.

Sourcing and Quality

No approved pharmaceutical product exists: Nefiracetam was never approved in the United States, the European Union or Japan, so no pharmacy-grade reference product is available anywhere to benchmark retail material against.
Certificate of analysis is the minimum bar: A batch-specific certificate showing identity and purity by high-performance liquid chromatography or mass spectrometry, plus heavy-metal and residual-solvent screens, is the only available substitute for regulatory oversight.
Retail racetam products test badly: In the analysis of ten racetam-labeled cognitive products, 75% of declared quantities were wrong, several declared drugs were absent, and undeclared drugs including phenibut and picamilon were present.
No vendor can be called reputable on evidence: No supplier publishes independent third-party assays for nefiracetam specifically, and the United States Food and Drug Administration has issued warning letters to established nootropic sellers, including Pure Nootropics, for marketing unapproved drugs.
Compounding pharmacies are an option only in Australia: Because nefiracetam sits in Schedule 4 of the Australian Poisons Standard, a prescription route exists there; elsewhere no legitimate compounding source can supply it.
Physical form affects dosing accuracy: Tablets and capsules are typically 400–600 mg, which forces coarse dose steps; bulk powder allows finer titration but requires a milligram-resolution scale, since volumetric scooping misestimates badly.

Practical Considerations

Time to effect: Single doses do not measurably affect cognition. Animal and human work alike show effects emerging with repeated daily dosing over seven days or more, and the trial endpoints were measured at 12 weeks.
Pitfall — expecting an acute effect: The most common error is judging the compound after one or two doses, concluding it does nothing, and escalating the dose. Steady state is not reached until roughly day 7.
Pitfall — omitting a choline source: Accelerated acetylcholine turnover without added choline is the standard explanation for racetam headache, and it drives a large share of early discontinuation.
Pitfall — open-ended use without monitoring: Because no human data extend past 12 weeks, indefinite dosing with no kidney or reproductive testing substitutes optimism about species-specificity for evidence.
Regulatory status: Unapproved in the United States, European Union and Japan; not scheduled by the United States Drug Enforcement Administration; prescription-only under Schedule 4 of the Australian Poisons Standard since 1 June 2019; sold elsewhere as a research chemical.
Cost and accessibility: Bulk powder is inexpensive per gram and widely sold online, but no insurer or national health system reimburses it anywhere, and no pharmacy outside Australia can legitimately dispense it.
Payer and sponsor incentives: The approved comparators for post-stroke apathy are cheap generics, so institutional payers have no financial reason to favor either option. No sponsor holds a patent incentive to fund confirmatory trials — a structural reason the evidence base stayed thin.

Interaction with Foundational Habits

Sleep: Indirect and potentially blunting. Potentiation of the brain’s main calming receptor produced sedation and prolonged anesthesia in animals, yet users also report daytime alertness. Practical handling: keep the last dose before mid-afternoon so the 3–5 hour parent exposure clears before sleep onset.
Nutrition: Direct and potentiating. Absorption depends on lipid solubility, so a fat-containing meal or a tablespoon of olive oil improves uptake. Dietary choline — eggs, liver — or a choline supplement supports the acetylcholine turnover the compound accelerates. Grapefruit juice blocks clearance and is avoided.
Exercise: No documented interaction in either direction. Nothing suggests blunted training adaptation, and no trial measured strength, endurance or recovery. The one theoretical link is the animal testosterone signal, which would matter for training response if it translated; nothing indicates it does.
Stress management: Indirect and potentiating. The calming-receptor action and animal mood-model findings point the same way as breathing practice or meditation rather than against them. No human stress-hormone measurement has been published, so the interaction remains mechanistic rather than demonstrated.

Monitoring Protocol & Defining Success

Baseline testing is done before the first dose and is built around the two organ systems where animal toxicity appeared, plus the clearance route. A comprehensive metabolic panel establishes kidney filtration and liver enzymes; a urinalysis records concentrating ability; and for men a morning total testosterone with estradiol, and a semen analysis for anyone planning conception, fixes the reproductive starting point. Formal apathy or depression scoring at baseline is what makes any later change interpretable.

Ongoing monitoring repeats the same panel at 6 weeks and again at 12 weeks, then every 3–6 months if use continues past the studied window. Success is defined not by a biomarker moving but by a measurable fall in the baseline apathy or mood score, with kidney, liver and reproductive markers unchanged from baseline.

Biomarker	Optimal Functional Range	Why Measure It?	Context/Notes
Serum creatinine	0.7–1.0 mg/dL (men), 0.6–0.9 mg/dL (women)	Core kidney filtration marker	Conventional range extends to 1.3 mg/dL; trial exclusion was above 2.0 mg/dL, far looser than the functional target
Estimated glomerular filtration rate	Above 90 mL/min/1.73 m²	Confirms filtration reserve before loading the kidney with metabolites	eGFR is the calculated filtering rate of the kidneys; conventional practice tolerates above 60, trial exclusion was below 25
Blood urea nitrogen	10–16 mg/dL	Rises early with reduced filtration or dehydration	BUN is a nitrogen waste product; conventional range runs to 20 mg/dL, trial exclusion was above 30; interpret alongside hydration status
Urine specific gravity and osmolality	1.010–1.025; 500–800 mOsm/kg	Loss of concentrating ability was the earliest kidney signal in dogs	Collect a first-morning sample; a falling value with rising urine volume is the pattern of interest
Alanine aminotransferase	10–26 U/L (men), 8–22 U/L (women)	Liver health governs CYP3A4 clearance of the compound	ALT is a liver enzyme released when liver cells are stressed; conventional upper limits reach 40–55 U/L, well above the functional target
Total testosterone (men)	600–900 ng/dL	The animal toxicity signal began with falling testicular testosterone	Draw between 07:00 and 10:00 fasting; conventional range starts at 264 ng/dL, which would mask a meaningful individual decline
Estradiol (men)	20–30 pg/mL	Rose in dogs alongside the testicular lesion, making it a paired marker	Best paired with total testosterone from the same draw; use a sensitive assay, since standard assays are unreliable at male levels
Semen analysis (men planning conception)	Concentration above 15 million/mL, progressive motility above 32%, normal forms above 4%	Directly measures the endpoint damaged in both dogs and rats	No established nefiracetam-specific target exists, so track change from the individual’s own baseline rather than the reference cut-offs alone

Qualitative markers worth tracking alongside the laboratory panel:

Motivation and initiative — whether planned tasks actually get started, which is what the Apathy Scale measures
Mood stability across the day rather than peak mood
Cognitive clarity and word-finding, logged at a fixed time daily
Sleep onset latency and morning grogginess, the earliest signs of the calming-receptor action spilling into the night
Headache frequency, the practical readout of choline adequacy
Nausea or abdominal discomfort in the two hours after a dose

Emerging Research

Only one registered trial exists: NCT00001933, a mid-stage placebo-controlled study of 50 patients with mild-to-moderate Alzheimer’s disease run by the National Institute of Neurological Disorders and Stroke, completed in January 2002 and has never posted results.
No ongoing trials: A registry search in September 2026 returned that single record, marked completed. Nothing is recruiting anywhere, which is the central obstacle: every open question needs a trial that no sponsor currently funds.
Formulation chemistry could revive it: Buol et al., 2020 improved dissolution and solubility using co-crystals, addressing the poor water solubility that constrained earlier dosing. Better exposure at lower milligram loads would change the risk calculus.
CaMKII as a drug target: Moriguchi, 2011 frames nefiracetam within a broader effort to treat Alzheimer’s disease through calcium/calmodulin-dependent protein kinase II. Success for any agent in that class would strengthen the mechanistic case.
Seizure and brain-injury work continues: Lu et al., 2013 showed attenuation of post-ischemic non-convulsive seizures and protection against glutamate-induced cell death in rats, extending the neuroprotection line that has yet to reach any human test.
Evidence pointing the other way: The 2017 pooled comparison ranking nefiracetam last among ten agents, and the 2016 randomized failure in post-stroke apathy, are the two findings most likely to be confirmed rather than overturned by any larger trial.
The unclosed reproductive question: No human semen or testosterone study has ever been run on nefiracetam. Until one is, the species-specificity argument for the animal testicular findings rests on inference from metabolite profiles rather than on measurement in people.

Conclusion

Nefiracetam is a compound that never became a medicine. Built in Japan as an oral treatment for the thinking and mood problems that follow a stroke, it was carried through full-scale human testing and dropped in 2002 when the decisive trial did not deliver. What survives is a narrow and contested finding: in stroke patients who were also depressed, the higher of two daily doses improved motivation more than a dummy treatment did, and a later, much smaller attempt to repeat that result found nothing. The claimed memory benefit that drives most present-day interest rests on animal work; the human cognition trials that were run did not show it.

What people reported while taking it is unremarkable — mild stomach upset, headache and jitteriness, nothing severe recorded over twelve weeks. The uncomfortable part of the record is animal: dogs given very large doses developed kidney and testicular damage, and the kidney injury traces to a breakdown product that humans do not appear to form. The testicular injury has no such explanation, since rats showed it too, and nobody has tested sperm or hormone levels in people.

Two things shape how much weight the evidence can carry. Almost all of the laboratory, animal and safety work was produced by the company that owned the compound, and it also funded the stroke trials. And because the compound is no longer protected by a patent, no company is paying for further work on it.

Top - Benefits - Risks - Protocol

Nefiracetam for Health & Longevity

Motivation

Recommended Reading

Grokipedia

Examine

ConsumerLab

Systematic Reviews

Mechanism of Action

Historical Context & Evolution

Expected Benefits

High 🟩 🟩 🟩

Medium 🟩 🟩

Low 🟩

Reduced Apathy After Stroke ⚠️ Conflicted

Improved Mood in Severe Post-Stroke Depression ⚠️ Conflicted

Speculative 🟨

Memory and Learning Enhancement

Neuroprotection After Reduced Brain Blood Flow

Suppression of Established Seizures

Relief of Nerve-Injury Pain

Reduced Anxiety

Benefit-Modifying Factors

Potential Risks & Side Effects

High 🟥 🟥 🟥

Medium 🟥 🟥

Mild Gastrointestinal Upset

Low 🟥

Headache, Nervousness, and Fatigue

Adulterated or Mislabeled Product

Speculative 🟨

Testicular Injury and Reduced Sperm Quality

Renal Papillary Necrosis

Hemorrhagic Bladder Lesions

Sedation, Unsteadiness, and Additive Sedative Effects

Risk-Modifying Factors

Key Interactions & Contraindications

Risk Mitigation Strategies

Therapeutic Protocol

Discontinuation & Cycling

Sourcing and Quality

Practical Considerations

Interaction with Foundational Habits

Monitoring Protocol & Defining Success

Emerging Research

Conclusion